Zhi Xiang Jintai (688443.SH) has received approval for the clinical trial application of the research product GR2301 injection.

Zhixiang Jintai (688443.SH) announced that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's clinical trial application for GR2301 injection has been approved. The announcement shows that GR2301 injection is a recombinant humanized anti-IL-15 monoclonal antibody independently developed by the company, which can block the binding of IL-15 to IL-15R and IL-15 & IL-15R complex to IL-2R & IL-2R complex, inhibit the downstream JAK-STAT signaling pathway, and achieve the therapeutic effect of treating autoimmune diseases such as vitiligo caused by IL-15 expression imbalance.